April 26 2022- MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier American cannabis retailer, today announced the partial adjournment of its 2022 Annual and Special Meeting of Shareholders (“Annual Meeting”), with respect to Proposal 3, set forth in its Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on March 11, 2022 (the “Proxy Statement”) until May 19, 2022 at 9:00 AM (Pacific Time). The Annual Meeting was convened with respect to the other proposals set forth in the Proxy Statement with all such proposals having been approved.
The Annual Meeting will resume as a virtual meeting held via live audio webcast on the Internet on May 19, 2022, at 9:00 a.m. (Pacific Time) at web.lumiagm.com/243159945.
The Company adjourned the Annual Meeting, held on April 20, 2022, with respect to Proposal 3 to give itself additional time to solicit proxies with respect to that proposal. Proposal 3 is to approve an amendment to the MedMen Enterprises Inc. 2018 Stock and Incentive Plan to set the amount reserved for future issuance under the plan to 200,000,000 Class B Subordinate Voting Shares plus all shares underlying outstanding awards as of April 1, 2021, the effective date of the approval by the board of directors. Further information on Proposal 3 may be found in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on March 11, 2022.
Proposal 3 requires the affirmative vote of a majority of the outstanding Class B Subordinate Voting Shares entitled to vote at the Annual Meeting, and, for purposes of applicable Canadian securities laws, a majority of the votes cast on the proposal by the shareholders present in person or represented by proxy and entitled to vote at the Annual Meeting. The Company has determined that a further adjournment is necessary to allow shareholders who have not yet voted additional time to vote. The record date for determining stockholders eligible to vote at the Annual Meeting will remain the close of business on March 4, 2022.
The Company encourages all shareholders of record as of March 4, 2022 who have not yet voted on Proposal 3 to vote to approve Proposal 3 by 9:00 AM, Pacific Time, on May 17, 2022. If you have questions or need assistance voting your shares, please contact:
Alliance Advisors, LLC
200 Broadacres Drive, 3rd Floor
Bloomfield, New Jersey 07003
Toll Free: 800-429-6507
The Annual Meeting was convened on April 20, 2022 with respect to Proposals 1 (setting the number of directors at five), 2 (election of directors), and 4 (ratification of the Company’s public accounting firm), each as set forth in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on March 11, 2022, all of which were approved. The Company will file a Current Report on Form 8-K with the U.S. Securities and Exchange Commission, disclosing the voting results on those proposals.
MedMen is a premier American cannabis retailer with an operational footprint in California, Nevada, Illinois, Arizona, Massachusetts, and Florida. MedMen offers a robust selection of high-quality products, including MedMen-owned brands MedMen Red and LuxLyte through its premium retail stores, proprietary delivery service, as well as curbside and in-store pickup. MedMen Buds, an industry-first loyalty program, provides exclusive access to promotions, product drops and content. MedMen believes that a world where cannabis is legal and regulated is safer, healthier, and happier. Learn more about MedMen at www.medmen.com.